• Product name

    Anti-Bestrophin/BEST1 antibody
    See all Bestrophin/BEST1 primary antibodies
  • Description

    Rabbit polyclonal to Bestrophin/BEST1
  • Host species

  • Tested applications

    Suitable for: IP, WB, IHC-P, ICC/IFmore details
  • Species reactivity

    Reacts with: Human, Cynomolgus monkey
  • Immunogen

    Synthetic peptide corresponding to Human Bestrophin/BEST1 aa 595-614 (C terminal).

  • Positive control

    • Conditioned medium cultured RPE cells (the basal expression of Bestrophin/BEST1 is low in cultured cells).
  • General notes

     This product was previously labelled as Bestrophin




Our Abpromise guarantee covers the use of ab14929 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP 1/200.
WB 1/500. Predicted molecular weight: 68 kDa.
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF Use at an assay dependent concentration.


  • Function

    Forms calcium-sensitive chloride channels. Highly permeable to bicarbonate.
  • Tissue specificity

    Predominantly expressed in the basolateral membrane of the retinal pigment epithelium.
  • Involvement in disease

    Defects in BEST1 are the cause of vitelliform macular dystrophy type 2 (VMD2) [MIM:153700]; also known as Best macular dystrophy (BMD). VMD2 is an autosomal dominant form of macular degeneration that usually begins in childhood or adolescence. VMD2 is characterized by typical 'egg-yolk' macular lesions due to abnormal accumulation of lipofuscin within and beneath the retinal pigment epithelium cells. Progression of the disease leads to destruction of the retinal pigment epithelium and vision loss.
    Defects in BEST1 are the cause of retinitis pigmentosa type 50 (RP50) [MIM:613194]. A retinal dystrophy belonging to the group of pigmentary retinopathies. RP is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.
    Defects in BEST1 are a cause of adult-onset vitelliform macular dystrophy (AVMD) [MIM:608161]. AVMD is a rare autosomal dominant disorder with incomplete penetrance and highly variable expression. Patients usually become symptomatic in the fourth or fifth decade of life with a protracted disease of decreased visual acuity.
    Defects in BEST1 are the cause of bestrophinopathy autosomal recessive (ARB) [MIM:611809]. A retinopathy characterized by central visual loss, an absent electro-oculogram light rise, and a reduced electroretinogram.
    Defects in BEST1 are the cause of vitreoretinochoroidopathy autosomal dominant (ADVIRC) [MIM:193220]. A disorder characterized by vitreoretinochoroidal dystrophy. The clinical presentation is variable and may be associated with cataract, nanophthalmos, microcornea, shallow anterior chamber, and glaucoma.
  • Sequence similarities

    Belongs to the bestrophin family.
  • Post-translational

    Phosphorylated by PP2A.
  • Cellular localization

    Cell membrane. Basolateral cell membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • ARB antibody
    • BEST 1 antibody
    • BEST antibody
    • Best disease antibody
    • Best macular dystrophy antibody
    • BEST1 antibody
    • BEST1_HUMAN antibody
    • Best1V1Delta2 antibody
    • Bestrophin 1 antibody
    • Bestrophin-1 antibody
    • Bestrophin1 antibody
    • BMD antibody
    • mBest1 antibody
    • RP50 antibody
    • TU15B antibody
    • Vitelliform macular dystrophy 2 antibody
    • Vitelliform macular dystrophy antibody
    • Vitelliform macular dystrophy protein 2 antibody
    • VMD 2 antibody
    • VMD2 antibody
    see all


  • IHC image of ab14929 staining in human normal hippocampus formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab14929, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.


This product has been referenced in:

  • Gu Q  et al. Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations. Stem Cell Reports 9:366-380 (2017). Read more (PubMed: 28506532) »
  • Wu W  et al. Features specific to retinal pigment epithelium cells derived from three-dimensional human embryonic stem cell cultures - a new donor for cell therapy. Oncotarget 7:22819-33 (2016). Read more (PubMed: 27009841) »
See all 7 Publications for this product

Customer reviews and Q&As


Thank you very much for your patience.

I have checked the sequence similarity between human and rat proteins based on this similarity, my recommendations about the rat cross reactivity would be

- The sequence is 94% similar between the two species so we do not have any anti RPE65 ab that do not cross react with rat protein.


- ab14929 is anti Bestrophin antibody; it should not cross react with Rat protein because of low immunogen sequence homology. This antibody could be a good choice.

- ab59232 (anti MITF) seems not to be cross reacting with Rat.

- We do not have any human CRALBP antibody that would not cross react with RAT protein.

I hope this information is nevertheless helpful. Should you have any question please do not hesitate to ask.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up